Other highlights in the September 3 issue of JNCI
...anced Ovarian Cancer The chemotherapy regimen of carboplatin plus paclitaxel is as effective as cisplatin plus ...th the disease. Earlier studies had suggested that carboplatin plus paclitaxel might be better tolerated than cisplatin plus paxlitaxel. To test this hypothesis, A...Paclitaxel combination improves survival from small-cell lung cancer
...und that treatment with paclitaxel, etoposide, and carboplatin yielded better rates of survival and fewer side ef...ree-drug combination of paclitaxel, etoposide, and carboplatin was effective, safe, and well-tolerated, and therefore we conclude that its use is a reasonable trea...Study compares three weekly regimens of chemotherapy for lung cancer
...ns of paclitaxel in combination with full doses of carboplatin is reasonably well tolerated and the efficacy resu... compared three regimens of weekly paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer (NSCLC) and found that higher weekly doses of p...European trial finds old lung cancer treatment may still be best
...sed drugs in advanced lung cancer, cisplatinin and carboplatin (both in combination with paclitaxel) have conclu...ity of life was just as good as patients receiving carboplatin and paclitaxel. The phase III multi-national European trial involving 618 patients with advanced non...International study suggests carboplatin could be first-line chemotherapy drug for ovarian cancer
...s week's issue of THE LANCET suggest that the drug carboplatin could become a first-line chemotherapeutic agent f...orubicin, and cisplatin ( known as CAP) and use of carboplatin produce similar survival and progression-free survival rates. More recently, the taxane paclitaxel c...New drug boost for asbestos-related lung cancer sufferers
... first convincing demonstration that pemetrexed to carboplatin could be useful in the treatment of the disease'. Pemetrexed is an experimental drug being developed by pharmaceutical company Eli Lilley under the trade name Alimta. It is an anticancer drug based on being an analogue of the B-vitamin, folic acid. D...Newer lung cancer treatments extend survival longer than traditional regimens
...re treated with regimens containing paclitaxel and carboplatin survive longer than patients treated with older ci... regimen: paclitaxel and carboplatin; paclitaxel, carboplatin and gemcitabine; and paclitaxel, carboplatin, and vinorelbine. Data from these trials were compared......at is comparing the standard regimen of TAXOL plus carboplatin every three weeks to the aforementioned weekly regimen. An estimated 164,100 new cases of lung cancer will be diagnosed in 2000, accounting for 14 percent of cancer diagnoses, according the American Cancer Society. NSCLC accounts for 75 to 80 perc......d weekly doses of two standard chemotherapy drugs, carboplatin and taxol, used together for the first time, in addition to radiation therapy five times a week for seven weeks. The patients in the study all had locally advanced cancer and/or cancer that had spread to nearby lymph nodes. Each patient was monitor......axel (Taxol), docetaxel(Taxotere), carboplatin (Paraplatin) and cisplatin (PlatinolAQ). However, the administration of these agents (particularly theiradministration in combination) frequently results in clinically importantneurotoxicity that poses certain risks and can limit the...... such as cisplatin and carboplatin. Cisplatin and carboplatin are widely used in the treatment of a variety ofco...mors. However, theadministration of cisplatin and carboplatin frequently results in clinicallyimportant toxicities, including kidney toxicity, vomiting, and bone ......ain tumor patientsreceiving the chemotherapy agent carboplatin delivered by opening theblood-brain barrier. ...e hearing loss were able to undergomore courses of carboplatin treatment before any loss occurred." Before the STS trials began, 15 (79 percent) of 19 simi......II study confirmed the efficacy of paclitaxel plus carboplatin in thetreatment of non-small cell lung cancer (NSCLC). These data were presented hereat the 34th annual meeting of the American Society of Clinical Oncology. This study was designed to compare paclitaxel/carboplatin tocisplatin/etoposide. T......al dataindicating that BNP7787 can protect against carboplatin associated toxicity. Ifwe are able to safely admi...er higher and more effective doses of cisplatinand carboplatin to cancer patients, this may lead to improved patient responserates." BNP7787 is currently in Phase...